Plus: Phase IIb setback for Spruce, Inventiva combination in MASH, and more

Plus: Venrock unveils $650M fund and more from Calypso, Isomorphic, Bayer, Flagship and Vertex

Less than 10 companies taking a shot at PCOS. With each testing a different MoA, they promise broad learnings

Plus: FDA clears Astellas’ therapy for hot flashes updates from Cullgen and SFJ-Serb

Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more

As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities

Decisions include GSK’s daprodustat, and two sBLAs for Regeneron’s Eylea

Clover readies COVID vaccine for submission, plus Veklury, Xalkori, Hexagon, Paige, Astellas, Rhythm

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy. Astellas Pharma Inc.

CEO Kerr sees ‘encouraging’ progress in area where biotechs have struggled to raise money